[DOI] [PMC free article] [PubMed] [Google Scholar] 35.Loomba R., Hartman M.L., Lawitz E.J., Vuppalanchi R., Boursier J., Bugianesi E., Yoneda M., Behling C., Cummings O.W., Tang Y., et al
That study enrolled 3,417 adults with obesity or overweight and without type 2 diabetes, and showed a mean weight loss of 22.7% at 68 weeks in patients who remained on treatment
Until recently, the published studies with the new obesity pharmacotherapies have had up to 2 years follow-up [12]
Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian cohort study
Long-Acting strategies for GLP-1 RAs, source: Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP, Drug Design, Development and Therapy, Oral Formulation The only available oral GLP-1RA is semaglutide (Rybelsus, Novo Nordisk)